Intellia Therapeutics, Inc. financial data

Symbol
NTLA on Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
Location
40 Erie Street, Suite 130, Cambridge, MA
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 861 % -0.22%
Debt-to-equity 22 %
Return On Equity -49.7 % -19.4%
Return On Assets -40.7 % -20.1%
Operating Margin -1.14K % -31.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 102M shares +14.8%
Common Stock, Shares, Outstanding 98.3M shares +11.3%
Entity Public Float 3.57B USD -8.33%
Common Stock, Value, Issued 10K USD +11.1%
Weighted Average Number of Shares Outstanding, Basic 97M shares +9.97%
Weighted Average Number of Shares Outstanding, Diluted 97M shares +9.97%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 46M USD -13.3%
Research and Development Expense 449M USD +9.69%
General and Administrative Expense 121M USD +16.8%
Costs and Expenses 570M USD +11.1%
Operating Income (Loss) -524M USD -13.9%
Net Income (Loss) Attributable to Parent -509M USD -12.2%
Earnings Per Share, Basic -5.49 USD/shares -0.92%
Earnings Per Share, Diluted -5.49 USD/shares -0.92%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 131M USD -23.8%
Marketable Securities, Current 560M USD -23.9%
Accounts Receivable, after Allowance for Credit Loss, Current 12.3M USD +144%
Assets, Current 757M USD -19.4%
Property, Plant and Equipment, Net 30.3M USD -8.8%
Operating Lease, Right-of-Use Asset 105M USD -14.7%
Assets 1.19B USD -9.95%
Accounts Payable, Current 18.8M USD +61.7%
Employee-related Liabilities, Current 14.9M USD -5.17%
Accrued Liabilities, Current 45.1M USD -8.9%
Contract with Customer, Liability, Current 22.2M USD +1.14%
Liabilities, Current 105M USD +5.25%
Contract with Customer, Liability, Noncurrent 28.1M USD +117%
Operating Lease, Liability, Noncurrent 87.3M USD -17.3%
Other Liabilities, Noncurrent 10.8M USD
Liabilities 220M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.16M USD +70.1%
Retained Earnings (Accumulated Deficit) -1.91B USD -36.2%
Stockholders' Equity Attributable to Parent 971M USD -12.1%
Liabilities and Equity 1.19B USD -9.95%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -121M USD -10.4%
Net Cash Provided by (Used in) Financing Activities 60M USD +2601%
Net Cash Provided by (Used in) Investing Activities 5.9M USD
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 98.3M shares +11.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -54.8M USD +76.1%
Deferred Tax Assets, Valuation Allowance 616M USD +35.5%
Deferred Tax Assets, Gross 648M USD +31.9%
Operating Lease, Liability 115M USD -11.8%
Payments to Acquire Property, Plant, and Equipment 2.51M USD -34.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -508M USD -13.5%
Lessee, Operating Lease, Liability, to be Paid 147M USD -14%
Property, Plant and Equipment, Gross 72.6M USD +18.8%
Operating Lease, Liability, Current 19M USD +13.2%
Lessee, Operating Lease, Liability, to be Paid, Year Two 25.9M USD +4.02%
Lessee, Operating Lease, Liability, to be Paid, Year One 26.4M USD +3.79%
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 31.2M USD -21.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 25.1M USD -3.06%
Deferred Tax Assets, Operating Loss Carryforwards 259M USD +12.8%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 17.5M USD -30%
Depreciation, Depletion and Amortization 2.51M USD +22.5%
Deferred Tax Assets, Net of Valuation Allowance 32.4M USD -11.9%
Share-based Payment Arrangement, Expense 145M USD +28.1%